StockData

Entera Bio vs Inmune Bio

ENTX and INMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENTX and INMB compare

Entera Bio is the larger company, worth 19 times as much as Inmune Bio ($519M against $26.6M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENTXINMB
Size and price
Market cap$519M$26.6M
Share price$3.00$0.960
Change, 1 year10.7%−32.4%
Change, 5 years−12.5%−92.8%
Beta (5Y)−0.342.98
Employees206
StockData Score
Total score66
Valuation score01 (better)
Growth score00
Performance score00
Health score6 (better)5
Dividend score00
Valuation
P/B71.5×1.3× (better)
FCF yield−2.1%–
Growth
Revenue growth (TTM)−100%–
Revenue growth, 5Y average−35.1%35.4% (better)
EPS growth, 5Y average−17.9%–
Profitability
Return on equity−139%−74.8% (better)
Return on invested capital−966%–
Financial health
Debt / equity0.000.00
Current ratio8.98 (better)4.04
Altman Z-score14.32 (better)−10.47
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield−0.01%–
Shareholder yield−0.01%0.00% (better)
Ownership
Held by institutions6.2%15.7%
Held by insiders11.3%16.7%
Insider net buying, 12 months$141K–
Short interest, % of float4.6%11.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.